Open AccessClinical activity of regorafenib in PDGFRA-mutated gastrointestinal stromal tumor
Author(s) -
Thomas Grellety,
Michèle Kind,
JeanMichel Coindre,
Antoîne Italiano
Publication year - 2015
Publication title -
future science oa
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.825
H-Index - 23
ISSN - 2056-5623
DOI - 10.4155/fso.15.33
Subject(s) - pdgfra , regorafenib , gist , imatinib , stromal tumor , cancer research , imatinib mesylate , sunitinib , sarcoma , medicine , stromal cell , colorectal cancer , pathology , cancer , myeloid leukemia
Gastrointestinal stromal tumor (GIST) is the most frequent mesenchymal tumor of the gastrointestinal tract and one of the most frequent sarcoma. Mutually exclusive KIT and PDGFRA mutations are central events in GIST pathogenesis, and their understanding is crucial because specific treatment targeting oncogenic KIT and PDGFRA activation (especially imatinib) has become available. The most frequent PDGFRA mutation (D842V) is associated with primary resistance to imatinib. Data related to regorafenib efficacy in PDGFRA -mutated GIST are lacking. We report here a case report of a prolonged response with regorafenib in a patient with a PDGFRA- mutated GIST.